| ISIN | CH0269987423 |
|---|---|
| Valor Number | 26998742 |
| Bloomberg Global ID | |
| Fund Name | Bellevue Biotech CA CHF |
| Fund Provider |
Bellevue Asset Management AG
Zürich, Switzerland Phone: +41 44 267 67 00 E-Mail: info@bellevue.ch Web: www.bellevue.ch |
| Fund Provider | Bellevue Asset Management AG |
| Representative in Switzerland | |
| Distributor(s) |
Zürcher Kantonalbank Zürich Phone: +41 44 293 93 93 |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Distribution |
| Home Country | Switzerland |
| Issuing Condition | Special conditions apply to the issue of units |
| Redemption Condition | Special conditions apply to the redemption of units |
| Investment Strategy *** | N/A |
| Peculiarities |
| Current Price * | 121.86 CHF | 10.12.2025 |
|---|---|---|
| Previous Price * | 121.33 CHF | 09.12.2025 |
| 52 Week High * | 126.55 CHF | 26.11.2025 |
| 52 Week Low * | 86.97 CHF | 10.04.2025 |
| NAV * | 121.86 CHF | 10.12.2025 |
| Issue Price * | ||
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 24,007,570 | |
| Unit/Share Assets *** | 6,548,440 | |
| Trading Information SIX | ||
| YTD Performance | +17.66% |
31.12.2024 - 10.12.2025
31.12.2024 10.12.2025 |
|---|---|---|
| 1 month | +3.68% |
10.11.2025 - 10.12.2025
10.11.2025 10.12.2025 |
| 3 months | +16.50% |
10.09.2025 - 10.12.2025
10.09.2025 10.12.2025 |
| 6 months | +24.37% |
10.06.2025 - 10.12.2025
10.06.2025 10.12.2025 |
| 1 year | +14.78% |
10.12.2024 - 10.12.2025
10.12.2024 10.12.2025 |
| 2 years | +33.71% |
11.12.2023 - 10.12.2025
11.12.2023 10.12.2025 |
| 3 years | +10.70% |
12.12.2022 - 10.12.2025
12.12.2022 10.12.2025 |
| 5 years | +8.92% |
10.12.2020 - 10.12.2025
10.12.2020 10.12.2025 |
| Equity Participation Rate in % | 85.72 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | 0.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc | 7.72% | |
|---|---|---|
| Gilead Sciences Inc | 7.52% | |
| Amgen Inc | 7.35% | |
| Regeneron Pharmaceuticals Inc | 5.59% | |
| Alnylam Pharmaceuticals Inc | 5.08% | |
| AstraZeneca PLC ADR | 4.27% | |
| Insmed Inc | 4.23% | |
| argenx SE ADR | 2.72% | |
| Biogen Inc | 2.12% | |
| BridgeBio Pharma Inc | 2.03% | |
| Last data update | 31.10.2025 | |
| TER | 1.52% |
|---|---|
| TER date | 30.09.2024 |
| Performance Fee *** | 10.00% |
| PTR | |
| Max. Management Fee *** | 1.80% |
| Ongoing Charges *** | |
|
SRRI ***
|
|
| SRRI date *** | 30.11.2025 |